Palatin (PTN) Technologies announced that preclinical data from the Company’s melanocortin 4 receptor, or MC4R, selective PL7737 obesity program will be highlighted in a poster presentation at ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults with a loss-of-function mutation in the MC4R gene ...
Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Primary ...
CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Food intake and energy expenditure were thought to be simultaneously controlled by the same group of neurons, but now new evidence shows that they are independently regulated by an anatomically ...
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI ...
An impressive large-scale genetic study, led by scientists at the University of Cambridge, has homed in on a number of specific variants in a single gene that can help people either lose or gain ...
CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results